PAR 4.08% 25.5¢ paradigm biopharmaceuticals limited..

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-71

  1. 9,806 Posts.
    lightbulb Created with Sketch. 1243
    Regional deals typically involve less orthodox stakeholders

    "Beef steriods" have propensity to play games but eventually come around due to own self interest.

    US deal also in mix it appears.

    MPS relegated to MOA study with potential to break even.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.